Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C

World Journal of Gastroenterology

Volumn 9, Issue 4, 2003, Pages 751-754

  Wang, Jian ^a   Xiang, Gui Ju ^b   Liu, Bing Xiang ^c  

^a ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Infectious Diseases   (China)

^c Shi Bei Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ASCORBIC ACID; ASPARTIC ACID; HEPATITIS C ANTIBODY; INTERLEUKIN 2 RECEPTOR; VIRUS RNA;

ADULT; ARTICLE; CELL SURFACE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NONHUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; PROTEIN DETERMINATION; RNA VIRUS; SERUM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS DETECTION;

EID: 0037624664     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i4.751     Document Type: Article

References (41)

1. Piekarska A, Sidorkiewicz M, Lewandowska U, Kuydowicz J. Evaluation of persistence of IFN-alpha treatment response in chronic hepatitis C patients according with HCV-RNA presence in PBMC. Pol Arch Med Wewn 2001; 106: 939-944
2. Piekarska A, Kuydowicz J, Omulecka A. Interferon alpha-treatment predictive response factors in group of adults patients with chronic hepatitis C. Pol Arch Med Wewn 2001; 106: 927-937
3. Patek K, McHutchison J. Peginterferon alpha-2b: A new approach to improving response in hepatitis C patients. Expert Opin Pharmacother 2001; 2: 1307-1315
4. Iwabuchi S, Takatsuka K. Dynamic of serum HCV RNA levels during IFN therapy in patients with chronic hepatitis C for prediction of outcome of IFN therapy and beneficial dosing. Nippon Rinsho 2001; 59: 1363-1368
5. Fornai C, Maggi F, Favilli F, Vatteroni ML, Pistello M, Marchi S, Ciccorossi P, Antonelli G, Bendinelli M. Rapid changes in hepatitis C virus quasispecies produced by a single dose of IFN-alpha in chronically infected patients. J Interferon Cytokine Res 2001; 21: 417-422
6. Malaguarnera M, Di Fazio I, Trovato BA, Pistone G, Mazzoleni G. Alpha-interferon (IFN-alpha) treatment of chronic hepatitis C: Analysis of some predictive factors for the response. Int J Clin Pharmacol Ther 2001; 39: 239-245
7. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, Rampello L. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001; 21: 273-278
8. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438
9. Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: Associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001; 46: 2060-2065
10. Suzuki T, Yonemura K, Miyaji T, Suzuki H, Takahira R, Fujigaki Y, Fujimoto T, Hishida A. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis. Intern Med 2001; 40: 708-712
11. Nishiguchi S, Shiomi S, Enomoto M, Lee C, Jomura H, Tamori A, Habu D, Takeda T, Yanagihara N, Shiraki K. Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C? J Gastroenterol 2001; 36: 486-891
12. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96: 157-164
13. Garcia-Suarez J, Burgaleta C, Hernanz N, Albarran F, Tobaruela P, Alvarez-Mon M. HCV-associated thrombocytopenia: Clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 2000; 110: 98-103
14. Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY, Chang WY. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000; 142: 431-437
15. Hino K, Yamaguchi Y, Fujiwara D, Katoh Y, Korenaga M, Okazaki M, Okuda M, Okita K. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: A prospective study. J Viral Hepat 2000; 7: 36-42
16. Sanders K, Dubois M, Pasquier C, Payen JL, Alric L, Duffault M, Vinel JP, Pascal JP, Puel J, Izopet J. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 2000; 74: 661-668
17. Poynard T, Daurat V, Chevret S, Mousalli J, Degos F, Bailly F, Borotto E, Buffet C, Bartolomei-Portal I, Richardet JP, Riachi G, Calmus Y, Brechot C, Vidaud M, Olivi M, Bedossa P, Riffaud PC, Chastang C. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: A randomized trial. For the multicentre GER-CYT-01 group. J Viral Hepat 1999; 6:381-386
18. Weiss G, Umlauft F, Urbanek M, Herold M, Lovevsky M, Offner F, Gordeuk VR. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999; 180: 1452-1458
19. Vertuani S, Bazzaro M, Gualandi G, Micheletti F, Marastoni M, Fortini C, Canella A, Marino M, Tomatis R, Traniello S, Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 2002; 32: 144-154
20. Fujiwara T, Kiura K, Ochi K, Matsubara H, Yamanari H, Shimomura H, Harada M. Giant negative T waves during interferon therapy in a patient with chronic hepatitis C. Intern Med 2001; 40: 105-109
21. Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000; 6: 149-154
22. Kakizaki S, Takagi H, Yamada T, Ichikawa T, Abe T, Sohara N, Kosone T, Kaneko M, Takezawa J, Takayama H, Nagamine T, Mori M. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. J Viral Hepat 1999; 6: 315-319
23. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, Everson GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert D. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: Effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999; 94: 3583-3588
24. Willson RA, Fischer SH, Ochs HD. Long-term interferon alpha maintenance therapy for chronic hepatitis C infection in a patient with common variable immune deficiency. J Clin Gastroenterol 1999; 29: 203-206
25. Fabris C, Del Forno M, Falleti E, Toniutto P, Pirisi M. Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-alpha) injection in chronic hepatitis C. Clin Exp Immunol 1999; 117: 556-560
26. Begemann F, Jablonowski H. Enhancing the response to interferon-alpha. J Clin Virol 1999; 13: 1-7
27. Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999; 34: 55-60
28. Yagura M, Murai S, Kojima H, Tokita H, Kamitsukasa H, Harada H. Interferon treatment in patients with chronic hepatitis C with normal alanine-aminotransferase activity. Hepatogastroenterology 1999; 46: 1094-1099
29. Seifarth C, Benninger J, Bohm BO, Wiest-Ladenburger U, Hahn EG, Hensen J. Augmentation of the immune response to islet cell antigens with development of diabetes mellitus caused by interferon-alpha therapy in chronic hepatitis C. Z Gastroenterol 1999; 37: 235-2239
30. Boran M, Cetin S. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Nephron 1999; 82: 22-26
31. Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, Spengler U. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J Gastroenterol 2002; 8: 562-566
32. Zeuzem S. The kinetics of hepatitis C virus infection. Clin Liver Dis 2001; 5: 917-930
33. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-355
34. Kawamura C, Nakajima S, Kuroki T, Monna T. Two-dimensional analysis of production of IL-6 and TNF-alpha can predict the efficacy of IFN-alpha therapy. Hepatogastroenterology 1999; 46: 2941-2945
35. Song ZQ, Hao F, Min F, Ma QY, Liu GD. Hepatitis C virus infection of human hepatoma cell line 7721 in vitro. World J Gastroenterol 2001; 7: 685-689
36. Fukutomi T, Fukutomi M, Iwao M, Watanabe H, Tanabe Y, Hiroshige K, Kinukawa N, Nakamuta M, Nawata H. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000; 6: 692-698
37. Xu JZ, Yang ZG, Le MZ, Wang MR, He CL, Sui YH. A study on pathogenicity of hepatitis G virus. World J Gastroenterol 2001; 7: 547-550
38. Li CP, Wang KX, Wang J, Pan BR. mIL-2R, T cell subsets and hepatitis C. World J Gastroenterol 2002; 8: 298-300
39. Jimenez-Saenz M, Rojas M, Pinar A, Salas E, Rebollo J, Carmona I, Herrerias-Esteban JM, Herrerias-Gutierrez JM. Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to alpha-interferon. J Gastroenterol Hepatol 2000; 15: 567-569
40. Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, Yang DL, Hao LJ. Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C. World J Gastroenterol 2000; 6: 805-811
41. Oketani M, Higashi T, Yamasaki N, Shinmyozu K, Osame M, Arima T. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. J Clin Gastroenterol 1999; 28: 49-51